<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975141</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004065-86</org_study_id>
    <nct_id>NCT02975141</nct_id>
  </id_info>
  <brief_title>Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer</brief_title>
  <acronym>AFFECT</acronym>
  <official_title>Gemcitabine and Nab-Paclitaxel Combined With the Oral Irreversible ErbB Family Blocker Afatinib in Patients With Metastatic Pancreatic Cancer: A Phase Ib Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. med. Volker Heinemann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study sets out to determine the maximum tolerated dose (MTD) of afatinib in combination&#xD;
      with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.&#xD;
      The identified MTD will serve as recommended phase II dose (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic ductal adenocarcinoma (PDAC) remains an almost uniformly lethal disease. Although&#xD;
      there has been significant progress in understanding of the underlying molecular biology of&#xD;
      pancreatic cancer, this progress has not translated into substantially better treatments.&#xD;
      Alarmingly, the number of pancreatic cancer cases is constantly rising and pancreatic cancer&#xD;
      will be the second most frequent cause of cancer related death by 2030.&#xD;
&#xD;
      Accordingly, novel therapeutic strategies for patients with pancreatic cancer are desperately&#xD;
      needed.&#xD;
&#xD;
      Recently, the combination of gemcitabine and nab-paclitaxel proofed to be superior when&#xD;
      compared to single agent gemcitabine (overall survival [OS] 8.7 months in the&#xD;
      nab-paclitaxel/gemcitabine group versus 6.6 months in the gemcitabine group; hazard ratio for&#xD;
      death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P&lt;0.001). Consequently, this&#xD;
      combination therapy is now regarded as a novel treatment option for patient with metastatic&#xD;
      pancreatic cancer and should therefore serve as a backbone for future clinical studies.&#xD;
&#xD;
      Preclinical studies suggest a significant role for ErbB signaling in the pathogenesis of&#xD;
      pancreatic cancer. Accordingly, targeting the family of ErbB receptor tyrosine kinases seems&#xD;
      to be a viable option to improve the outcome of patients with pancreatic cancer. Addition of&#xD;
      the selective reversible EGFR tyrosine kinase inhibitor erlotinib to gemcitabine&#xD;
      significantly improved progression-free survival and overall survival in metastatic&#xD;
      pancreatic cancer patients. However, the effect on median survival time in absolute values&#xD;
      between the two arms (erlotinib and gemcitabine versus gemcitabine alone) accounted for less&#xD;
      than a half month.&#xD;
&#xD;
      Afatinib is a selective, potent and irreversible ErbB family blocker. Unlike erlotinib,&#xD;
      afatinib covalently binds to and irreversibly blocks signalling from all homo- and&#xD;
      heterodimers formed by the ErbB family members EGFR (ErbB1), HER2 (ErbB2), ErbB3 and ErbB4.&#xD;
      Afatinib is applied orally once daily. Preclinical studies suggest that application of&#xD;
      afatinib should result in greater efficacy against tumor growth than application of&#xD;
      erlotinib.&#xD;
&#xD;
      Afatinib as monotherapy has a marketing authorization for the treatment of locally advanced&#xD;
      or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation/mutations for&#xD;
      daily doses up to 50 mg once daily. In a Phase I trial for safety and tolerability of&#xD;
      afatinib in combination with gemcitabine in patients with advanced solid tumors the maximum&#xD;
      tolerated dose (MTD) was 40 mg afatinib (given continuously once daily) plus 1000 mg/m2&#xD;
      gemcitabine on D1 and D8 of a 21-day cycle, with no dose-limiting toxicity in the respective&#xD;
      cohort. Accordingly, in another current Phase II trial of the sponsor for treatment of&#xD;
      metastatic pancreatic cancer the dose of 40 mg continuously orally once daily given afatinib&#xD;
      in combination with 1000 mg/m2 gemcitabine given on Day1, Day 8, and Day 15 of a 28-day cycle&#xD;
      against monotherapy with gemcitabine 1000 mg/m2 is used.&#xD;
&#xD;
      The investigators hypothesize that addition of afatinib to gemcitabine/nab-paclitaxel might&#xD;
      result in better anti-tumor activity.&#xD;
&#xD;
      Accordingly, the aim of this trial is to establish the MTD for afatinib in combination with&#xD;
      gemcitabine/nab-paclitaxel in order to proceed into Phase II trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of afatinib in combination with gemcitabine/nab-paclitaxel</measure>
    <time_frame>28 days after the first dose of chemotherapy</time_frame>
    <description>Completion of the first cycle of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RECIST measurements of target lesions (in cm/inches)</measure>
    <time_frame>18 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (in months)</measure>
    <time_frame>18 months</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (in months)</measure>
    <time_frame>18 months</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>18 months</time_frame>
    <description>Type, incidence, and severity of adverse events according to NCI CTCAE version 4.03. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Afatinib 40Mg Tab, Gemzar, Abraxane +1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level +1 Afatinib 40 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level 0 Afatinib 30 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level -1 Afatinib 30 mg Nab-paclitaxel 100 mg/m2 BSA Gemcitabine 800 mg/m2 BSA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane -2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level -2 Afatinib 30 mg Nab-paclitaxel 75 mg/m2 BSA Gemcitabine 600 mg/m2 BSA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib 30Mg Tab</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane -1</arm_group_label>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane -2</arm_group_label>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane 0</arm_group_label>
    <other_name>Giotrif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib 40Mg Tab</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Afatinib 40Mg Tab, Gemzar, Abraxane +1</arm_group_label>
    <other_name>Giotrif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemzar</intervention_name>
    <description>Chemotherapy Backbone</description>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane -1</arm_group_label>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane -2</arm_group_label>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane 0</arm_group_label>
    <arm_group_label>Afatinib 40Mg Tab, Gemzar, Abraxane +1</arm_group_label>
    <other_name>Gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>Chemotherapy Backbone</description>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane -1</arm_group_label>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane -2</arm_group_label>
    <arm_group_label>Afatinib 30Mg Tab, Gemzar, Abraxane 0</arm_group_label>
    <arm_group_label>Afatinib 40Mg Tab, Gemzar, Abraxane +1</arm_group_label>
    <other_name>nab-Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients ≥ 18 years of age and ≤ 75 years&#xD;
&#xD;
          2. Histologically (not cytologically) confirmed diagnosis of metastatic pancreatic ductal&#xD;
             adenocarcinoma (PDAC) [Stage IV according to UICC TNM edition 7 of 2009: each T, each&#xD;
             N, M1]&#xD;
&#xD;
          3. No option for surgical resection or radiation in curative intent&#xD;
&#xD;
          4. At least one unidimensionally measurable tumor lesion (according to RECIST 1.1)&#xD;
&#xD;
          5. ECOG performance status 0 - 1&#xD;
&#xD;
          6. Life expectancy at least 3 months&#xD;
&#xD;
          7. Adequate hepatic, renal and bone marrow function, defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5x109/L&#xD;
&#xD;
               -  Haemoglobin ≥ 9 g/dL 9&#xD;
&#xD;
               -  Thrombocytes ≥100x10/L&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5xULN.&#xD;
&#xD;
                    -  Patients with a biliary stent may be included provided that bilirubin level&#xD;
                       after stent insertion decreased to ≤ 1.5 x ULN and there is no cholangitis.&#xD;
&#xD;
               -  AST/GOT and/or ALT/GPT ≤ 2.5 x ULN or in case of liver metastasis ≤ 5 x ULN)&#xD;
&#xD;
               -  Serum creatinine within normal limits or creatinine clearance ≥60 mL/min/1.73 m2&#xD;
                  as calculated by CKD- EPI formula for patients with serum creatinine levels above&#xD;
                  or below the institutional normal value.&#xD;
&#xD;
          8. Acceptable coagulation studies defined as prothrombin time (or INR) and PTT ≤ 1.5 x&#xD;
             ULN&#xD;
&#xD;
          9. Stable/decreasing pain symptoms under pain medication or no pain within the last 2&#xD;
             weeks before first application of study medication (as reported and assessed by the&#xD;
             patient).&#xD;
&#xD;
         10. Females of childbearing potential (FCBP) must have a negative highly sensitive serum&#xD;
             pregnancy test within 7 days of the first application of study treatment and they must&#xD;
             agree to undergo a further pregnancy tests at monthly intervals and at the end of&#xD;
             treatment visit and FCBP must either agree to use and be able to take highly effective&#xD;
             contraceptive birth control methods (Pearl Index &lt; 1) or agree to practice complete&#xD;
             abstinence from heterosexual intercourse during the course of the study and for at&#xD;
             least 1 month after last application of study treatment. A female subject following&#xD;
             menarche is considered to be of childbearing potential unless she is naturally&#xD;
             amenorrhoeic for ≥ 1 year without an alternative medical reason, or unless she is&#xD;
             permanently sterile.&#xD;
&#xD;
         11. Males must agree to use condoms during the course of the trial and for at least 6&#xD;
             months after last administration of study drugs or practice complete abstinence from&#xD;
             heterosexual intercourse.&#xD;
&#xD;
         12. Signed and dated informed consent before the start of any specific protocol procedures&#xD;
&#xD;
         13. Patient's legal capacity to consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Locally advanced PDAC without metastasis&#xD;
&#xD;
          2. Evidence of ascites&#xD;
&#xD;
          3. Known metastatic disease to the brain. Brain imaging is required in symptomatic&#xD;
             patients to rule out brain metastases, but is not required in asymptomatic patients.&#xD;
&#xD;
          4. Previous palliative chemotherapy or other palliative systemic tumor therapy for&#xD;
             metastatic disease of PDAC&#xD;
&#xD;
          5. Previous gemcitabine treatment with exception of gemcitabine treatment applied as&#xD;
             monotherapy in the adjuvant setting (after potential curative R0 or R1 resection) and&#xD;
             if the adjuvant single-agent gemcitabine chemotherapy was terminated at least 6 months&#xD;
             before study entry&#xD;
&#xD;
          6. Previous radiotherapy of PDAC&#xD;
&#xD;
          7. Previous ErbB family directed therapy for PDAC (e. g. erlotinib, cetuximab,&#xD;
             trastuzumab, lapatinib)&#xD;
&#xD;
          8. Any major surgery within the last 4 weeks before study entry&#xD;
&#xD;
          9. Clinical significant decrease in performance status within 2 weeks of intended first&#xD;
             application of study medication (by medical history)&#xD;
&#xD;
         10. Severe tumor-related cachexia and/or known weight loss &gt;15% within one month before&#xD;
             study enrollment&#xD;
&#xD;
         11. Pre-existing polyneuropathy ≥ grade 2 according to CTCAE version 4.03&#xD;
&#xD;
         12. LDH &gt;2.5xULN&#xD;
&#xD;
         13. Significant (≥ 20%) decrease in serum albumin levels within 2 weeks of intended first&#xD;
             application of study medication (by medical history)&#xD;
&#xD;
         14. Gastrointestinal disorders that might interfere with the absorption of the study drug&#xD;
             and gastrointestinal disorders with diarrhoea as a major symptom (e.g. Crohn's&#xD;
             disease, malabsorption), and chronic diarrhoea of any aetiology CTCAE version 4.03&#xD;
             grade ≥ 2&#xD;
&#xD;
         15. Medical history of interstitial lung disease (ILD) or pulmonary fibrosis or severe&#xD;
             COPD&#xD;
&#xD;
         16. Liver cirrhosis Child-Pugh other than class A&#xD;
&#xD;
         17. Known coagulopathy or bleeding disorder&#xD;
&#xD;
         18. History of connective tissue disorders (e.g. lupus, scleroderma,arteritis nods)&#xD;
&#xD;
         19. Any other severe concomitant disease or disorder, which could influence patient's&#xD;
             ability to participate in the study and his/her safety during the study or interfere&#xD;
             with interpretation of study results e.g. active infection, uncontrolled hypertension,&#xD;
             clinically significant cardiovascular disease e.g. cerebral vascular accident (≤ 6&#xD;
             months before study start), myocardial infarction (≤ 6 months before study start),&#xD;
             unstable angina, heart failure ≥ NYHA functional classification system grade 2, severe&#xD;
             cardiac arrhythmia requiring medication, metabolic dysfunction, severe renal disorder.&#xD;
&#xD;
         20. Any other malignancies than PDAC within the last 5 years before study start, except&#xD;
             for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin&#xD;
             cancer&#xD;
&#xD;
         21. Hypersensitivity to afatinib, nab-paclitaxel, or gemcitabine or to any of the&#xD;
             excipients or to compounds with similar chemical or biologic composition&#xD;
&#xD;
         22. Continuing abuse of alcohol,drugs,or medical drugs&#xD;
&#xD;
         23. Pregnant or breast-feeding females or FCBPs unable to either perform highly effective&#xD;
             contraceptive measures or practice complete abstinence from heterosexual intercourse&#xD;
&#xD;
         24. Current or recent (within 4 weeks prior to first application of study treatment)&#xD;
             treatment with an investigational drug or participation in an investigational clinical&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich - Klinikum Großhadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig-Maximilians - University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Volker Heinemann</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Palliative Chemotherapy</keyword>
  <keyword>Afatinib</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>nab-paclitaxel</keyword>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

